Good
Mostly Aligned
Patient Risk:
Low
Summary
The dosing rationale and efficacy statement appear consistent with the provided label excerpts for gabapentin postherpetic neuralgia (Section 2.1). However, the evaluation cannot fully verify exact wording/structure against the official label because the prompt indicates only excerpted label text was available, not the complete authoritative FDA label text.
Category Scores
Accurate Statements
Initiation on Day 1 as 300 mg once daily, Day 2 as 600 mg/day (300 mg twice daily), and Day 3 as 900 mg/day (300 mg three times a day) for adults with postherpetic neuralgia, with subsequent titration up to 1800 mg/day (600 mg three times daily) as needed for pain relief.
Supported by provided label excerpt in Section 2.1: initiation Day 1–3 (300 mg single dose; 600 mg/day 300 mg BID; 900 mg/day 300 mg TID) and titration up to 1800 mg/day (600 mg TID).
Efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day with comparable effects across the dose range; additional benefit of doses greater than 1800 mg/day was not demonstrated.
Supported by provided label excerpt in Section 2.1: studied range up to 3600 mg/day and statement that additional benefit >1800 mg/day was not demonstrated.
Unsupported Statements
Contradictions
Important Omissions
The claim does not specify that titration should be limited to 1800 mg/day as the maximum recommended dose (it implies this) and does not mention the exact phrasing that efficacy was demonstrated with comparable effects across the dose range (it partially includes this).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claim matches the provided Section 2.1 titration and maximum dose for postherpetic neuralgia and accurately includes the label’s statement about lack of additional benefit above 1800 mg/day.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Unable to fully audit exact FDA label wording/structure because only excerpts were available; verification would require the exact Section 2.1 FDA label text.
Suggested Improvement
Quote or include the exact FDA label language from Section 2.1 for the Day 1–3 titration, the 1800 mg/day maximum, and the statement about no additional benefit above 1800 mg/day.